相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2012
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Jazz Pharmaceuticals and AbCellera signed a preclinical collaboration to develop T-cell engaging multispecific antibodies for gastrointestinal and other solid tumors. - AbCellera will receive $56 million upfront for two initial programs, with an additional $28 million upon launching a third program within 12 months. - Each program could yield up to $792 million in option fees and milestone payments, plus tiered mid-single-digit to low double-digit royalties on net sales. - The partnership may expand to as many as five total programs, potentially pushing the deal's total value above $4 billion.
- AbCellera has appointed Dr. Lynn Seely, an experienced biopharmaceutical executive, to its Board of Directors as an independent director. - Dr. Seely previously led the clinical development of Xtandi (enzalutamide) at Medivation through global approvals, culminating in a $14 billion acquisition by Pfizer. - As CEO of Myovant Sciences, she successfully commercialized Myfembree and Orgovyx, demonstrating expertise in endocrinology and women's health. - Dr. Seely currently serves as president and CEO of Lyell Immunopharma, advancing next-generation CAR T-cell therapies for hematologic malignancies and solid tumors.
- AbCellera has dosed the first patients in the Phase 2 portion of its clinical trial for ABCL635, a potential first-in-class non-hormonal treatment for moderate-to-severe vasomotor symptoms associated with menopause. - The Phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate ABCL635's efficacy in reducing hot flash frequency and severity in 80 postmenopausal women. - ABCL635 specifically targets NK3R, a G protein-coupled receptor on KNDy neurons in the hypothalamus, representing the first program from AbCellera's GPCR platform to advance into clinical development. - The company anticipates top-line clinical results for both Phase 1 and Phase 2 portions in Q3 2026, following encouraging safety and pharmacodynamic data from the Phase 1 dose escalation study.
- British Columbia has launched an eight-bed clinical trials unit at Mount Saint Joseph Hospital, marking the province's first facility capable of conducting Phase 1 clinical trials for non-oncology conditions. - The $4 million government investment addresses a critical gap in early-stage drug development, allowing local biotech companies to test antibody treatments, gene therapies, and vaccines in humans for the first time. - The facility is expected to strengthen B.C.'s life sciences ecosystem by enabling companies to retain intellectual property locally and attract high-value licensing agreements with global pharmaceutical companies. - Michael Smith Health Research BC contributed an additional $1.2 million to support the unit and establish a new UBC professorship in clinical pharmacology and therapeutics.
- AbCellera's novel anti-OX40L monoclonal antibody ABCL575 demonstrates potent inhibition of inflammatory pathways in preclinical studies for moderate-to-severe atopic dermatitis treatment. - The drug candidate features a modified Fc domain providing a predicted human half-life exceeding 60 days, potentially enabling less frequent dosing compared to existing treatments. - ABCL575 targets OX40L, an upstream driver of the inflammatory cascade, which may provide broader inhibition of inflammatory pathways and more durable responses than currently approved biologics.
- AbbVie reports significant market penetration for Skyrizi and Rinvoq in IBD indications, capturing approximately 50% market share in Crohn's disease and ulcerative colitis treatment spaces. - Despite Humira's 32% sales decline following biosimilar entry in 2023, only 20% of patients have transitioned to biosimilars, with many physicians preferring AbbVie's newer immunology drugs. - The company is exploring combination therapy potential, particularly investigating TL1A therapies with Skyrizi, while also advancing its neurology pipeline with tavapadon showing promising Phase III results in Parkinson's disease.
- Alphabet's DeepMind has established Isomorphic Labs, a standalone AI-driven drug discovery company that will leverage the breakthrough AlphaFold protein structure prediction technology. - The new venture will be led by DeepMind founder Demis Hassabis and aims to revolutionize drug discovery by implementing an AI-first approach while building partnerships with pharmaceutical companies. - Isomorphic Labs will utilize DeepMind's AlphaFold2 database, which has successfully mapped nearly all human proteins and achieved sufficient precision for drug design in one-third of its protein models.
